Results

1–3 of 3 results for sustained-release

12-Month Ocular Pharmacokinetic Study of EYP-1901 a Sustained-Release Intravitreal Formulation of the Tyrosine Kinase Inhibitor Vorolanib
Rishi P. Singh, MD
Annual Meeting Talks
2023
Subgroup Analyses of the Phase 1 DAVIO Trial of EYP-1901 Showing Reduced Treatment Burden in Wet Age-related Macular Degeneration
Philip P Storey, MD, MPH
Annual Meeting Talks
2023
Interim Safety and Efficacy Results From the Phase 1 HELIOS Trial of Sustained-Release Axitinib Implant (OTX-TKI) for NPDR
Dilsher S. Dhoot, MD
Annual Meeting Talks
2024